Heitz F et al. [7] previously reported that shortest interval for triple-negative patients (22 months), and longer intervals for HER2-positive (30 months) and ER+/HER2- (63.5 months) breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.